{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:16:05Z","timestamp":1791288965936,"version":"4.3.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.gim.2025.101405","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:47:19Z","timestamp":1741880839000},"page":"101405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pegvaliase therapy for phenylketonuria: Real-world safety, efficacy, and medication access outcomes in a pharmacist-led pegvaliase program"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7957-1406","authenticated-orcid":false,"given":"Sofia","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia L.","family":"Zagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha R.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Ranasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine R.","family":"Jarnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gim.2025.101405_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet Med"},{"issue":"26","key":"10.1016\/j.gim.2025.101405_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202401353","article-title":"Current advances and material innovations in the search for novel treatments of phenylketonuria","volume":"13","author":"Delbreil","year":"2024","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"10.1016\/j.gim.2025.101405_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101289","article-title":"Phenylalanine hydroxylase deficiency diagnosis and management: a 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Smith","year":"2025","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2025.101405_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1542\/peds.32.3.338","article-title":"A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants","volume":"32","author":"Guthrie","year":"1963","journal-title":"Pediatrics"},{"issue":"9586","key":"10.1016\/j.gim.2025.101405_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.gim.2025.101405_bib6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.gim.2025.101405_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10545-012-9464-3","article-title":"Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria","volume":"35","author":"Leuret","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.gim.2025.101405_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ymgme.2011.10.014","article-title":"START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients","volume":"105","author":"Utz","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.gim.2025.101405_bib9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41436-018-0403-z","article-title":"Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria","volume":"21","author":"Longo","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2025.101405_bib10","article-title":"Pegvaliase for the treatment of phenylketonuria: final results of a long-term phase 3 clinical trial program","volume":"39","author":"Harding","year":"2024","journal-title":"Mol Genet Metab Rep"},{"issue":"1-2","key":"10.1016\/j.gim.2025.101405_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2019.07.018","article-title":"Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria","volume":"128","author":"Zori","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2025.101405_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2025.101405_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13023-018-0858-7","article-title":"Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study","volume":"13","author":"Longo","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gim.2025.101405_bib15","article-title":"Use of pegvaliase in the management of phenylketonuria: case series of early experience in US clinics","volume":"28","author":"Adams","year":"2021","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gim.2025.101405_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107564","article-title":"Two years of pegvaliase in Germany: experiences and best practice recommendations","volume":"139","author":"Kr\u00e4mer","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2025.101405_bib17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymgme.2021.05.006","article-title":"Palynziq clinic: one year and 43 patients later","volume":"133","author":"Lah","year":"2021","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2025.101405_bib18","article-title":"First 1.5 years of pegvaliase clinic: experiences and outcomes","volume":"24","author":"Sacharow","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.gim.2025.101405_bib19","article-title":"Management of patients with phenylketonuria (PKU) under enzyme replacement therapy: an Italian model (expert opinion)","volume":"39","author":"Scala","year":"2024","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.gim.2025.101405_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"4","key":"10.1016\/j.gim.2025.101405_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson","year":"2006","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.gim.2025.101405_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108151","article-title":"Pegvaliase therapy for phenylketonuria: real-world case series and clinical insights","volume":"142","author":"Scala","year":"2024","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"10.1016\/j.gim.2025.101405_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2019.05.006","article-title":"Pegvaliase: immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy","volume":"128","author":"Hausmann","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2025.101405_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/(SICI)1096-9926(199603)53:3<176::AID-TERA5>3.0.CO;2-2","article-title":"Maternal phenylketonuria: a metabolic teratogen","volume":"53","author":"Levy","year":"1996","journal-title":"Teratology"},{"issue":"3","key":"10.1016\/j.gim.2025.101405_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108152","article-title":"Outcomes in 14 live births resulting from Pegvaliase-treated pregnancies in PKU-affected females","volume":"141","author":"Bier","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2025.101405_bib28","article-title":"Continuation of pegvaliase treatment during pregnancy: a case report","volume":"26","author":"Boyer","year":"2021","journal-title":"Mol Genet Metab Rep"},{"issue":"Supp 1","key":"10.1016\/j.gim.2025.101405_bib29","article-title":"P.17 Successful outcomes with continued pegvaliase-pqpz treatment throughout pregnancy and lactation in a PKU patient","volume":"141","author":"Koesky","year":"2024","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2025.101405_bib30","article-title":"Reinstitution of pegvaliase therapy during lactation","volume":"33","author":"Rohr","year":"2022","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.gim.2025.101405_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-023-02751-0","article-title":"Nutrition management of PKU with pegvaliase therapy: update of the web-based PKU nutrition management guideline recommendations","volume":"18","author":"Cunningham","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.gim.2025.101405_bib32","series-title":"Pegvaliase. Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"issue":"1","key":"10.1016\/j.gim.2025.101405_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12920-024-01847-1","article-title":"First successful outcomes of pegvaliase (PALYNZIQ) in children","volume":"17","author":"Alfadhel","year":"2024","journal-title":"BMC Med Genomics"},{"issue":"3","key":"10.1016\/j.gim.2025.101405_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/apa.17492","article-title":"Neurocognitive functioning remained unchanged in adults with phenylketonuria: report of a 15-year follow-up","volume":"114","author":"Feldmann","year":"2025","journal-title":"Acta Paediatr"},{"issue":"4s","key":"10.1016\/j.gim.2025.101405_bib37","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/j.japh.2021.01.001","article-title":"Analysis of prior authorization success and timeliness at a community-based specialty care pharmacy","volume":"61","author":"Hecht","year":"2021","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.gim.2025.101405_bib38","series-title":"Pharmacy Practice News","year":"2025"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:41:22Z","timestamp":1780281682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360025000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1098360025000528"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101405","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegvaliase therapy for phenylketonuria: Real-world safety, efficacy, and medication access outcomes in a pharmacist-led pegvaliase program","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101405"}}